Janney Montgomery Scott LLC Takes Position in Progyny, Inc. (NASDAQ:PGNY)

Janney Montgomery Scott LLC bought a new position in Progyny, Inc. (NASDAQ:PGNY - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 65,153 shares of the company's stock, valued at approximately $1,124,000. Janney Montgomery Scott LLC owned about 0.08% of Progyny as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Leibman Financial Services Inc. grew its holdings in shares of Progyny by 100.7% in the fourth quarter. Leibman Financial Services Inc. now owns 63,509 shares of the company's stock worth $1,096,000 after purchasing an additional 31,872 shares during the last quarter. Fort Washington Investment Advisors Inc. OH boosted its holdings in Progyny by 90.1% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock valued at $25,319,000 after acquiring an additional 695,740 shares in the last quarter. Kornitzer Capital Management Inc. KS boosted its holdings in Progyny by 15.7% in the third quarter. Kornitzer Capital Management Inc. KS now owns 976,501 shares of the company's stock valued at $16,366,000 after acquiring an additional 132,672 shares in the last quarter. Aurora Investment Counsel bought a new stake in Progyny in the third quarter valued at $1,280,000. Finally, Clear Harbor Asset Management LLC bought a new stake in Progyny in the fourth quarter valued at $989,000. Institutional investors own 94.93% of the company's stock.

Progyny Trading Up 0.4 %

Shares of Progyny stock traded up $0.09 during trading on Friday, hitting $21.92. 1,557,297 shares of the stock traded hands, compared to its average volume of 1,883,574. The firm has a market cap of $1.87 billion, a P/E ratio of 37.79, a price-to-earnings-growth ratio of 2.18 and a beta of 1.34. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $42.08. The stock's fifty day simple moving average is $18.34 and its 200 day simple moving average is $18.96.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The company had revenue of $286.63 million during the quarter, compared to analysts' expectations of $296.85 million. During the same quarter last year, the firm earned $0.16 EPS. Progyny's revenue for the quarter was up 2.0% on a year-over-year basis. As a group, equities analysts expect that Progyny, Inc. will post 0.6 EPS for the current year.

Insider Buying and Selling at Progyny

In other news, CEO Peter Anevski bought 209,500 shares of the firm's stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the acquisition, the chief executive officer now directly owns 441,463 shares of the company's stock, valued at $6,392,384.24. This trade represents a 90.32 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman David J. Schlanger bought 150,000 shares of the firm's stock in a transaction that occurred on Thursday, December 26th. The shares were purchased at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the acquisition, the chairman now directly owns 228,269 shares of the company's stock, valued at approximately $3,350,988.92. This trade represents a 191.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

PGNY has been the topic of several recent analyst reports. Barclays cut their price target on shares of Progyny from $30.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, November 14th. JPMorgan Chase & Co. raised their price objective on Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. Canaccord Genuity Group lowered their price objective on Progyny from $18.00 to $17.00 and set a "hold" rating for the company in a research report on Wednesday, November 13th. Bank of America lowered their price objective on Progyny from $22.00 to $21.00 and set a "buy" rating for the company in a research report on Wednesday, November 13th. Finally, Truist Financial reissued a "hold" rating and set a $19.00 price objective (down previously from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Nine investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, Progyny presently has a consensus rating of "Hold" and an average price target of $25.50.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.